Xiaoqing (Cathy) Cheng

Research Program Breast Cancer Research, Mechanisms of Cancer Biology Program
Xiaoqing (Cathy) Cheng

Researcher Background

Primary Academic Title

Instructor, School of Medicine, WashU Medicine

Training

  • 2017 - 2018: Postdoctoral Associate, Johns Hopkins University, Baltimore, MA
  • 2018 - 2022: Postdoctoral Associate, WashU Medicine, St. Louis, MO
  • 2022 - 2024: Staff Scientist, WashU Medicine, St. Louis, MO

Education

  • 2017: PhD , Wuhan University, Wuhan, China

Research & Selected Publications

Research Interest

My research interests are focused on metastatic breast cancer with HER2 activating mutations and metastatic clear cell renal cell carcinoma with VHL mutations. Specifically, I study the genetic and epigenetic determinants for the drug response activity, the molecular mechanism of the metastasis and invasion process, and the regulation of tumor microenvironment interplay in the metastatic organs, especially the metastasis in the lung and the brain. Utilizing the multiple omics and novel mouse and tumor organoid models, I aim to comprehend the effects of drug resistance and sensitivity to figure out better therapy strategies and precision treatment for individual patients based on the plasticity and heterogeneity of the cancer types

Research Publications

HER2; p53 Co-mutated Cancers Show Increased Histone Acetylation and are Sensitive to Neratinib plus Trastuzumab Deruxtecan.
Authors:

Cheng X, Hsia J, Iraheta J, one or more additional authors omitted Bose R

Journal & Year:

bioRxiv • 2025

Cerebellum metastasis model of HER2-positive breast cancer unveils key role of IL34-induced Arg1+ macrophages.
Authors:

Cheng X, Patel KK, Zhou B, one or more additional authors omitted Bose R

Journal & Year:

bioRxiv • 2025

Breast Cancer Mutations HER2V777L and PIK3CAH1047R Activate the p21-CDK4/6-Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance.
Authors:

Cheng X, Sun Y, Highkin M, one or more additional authors omitted Bose R

Journal & Year:

Cancer Res • 2023